Skip to main content
. Author manuscript; available in PMC: 2018 Apr 9.
Published in final edited form as: Leukemia. 2009 Feb 19;23(7):1320–1328. doi: 10.1038/leu.2009.19

Figure 2.

Figure 2

Binding affinity and stability of cyclin D1 peptides with HLA-A*0201 molecules. Peptide binding assay showing (A) binding affinity and (B) stability (fluorescence index) of two cyclin D1 peptides P101 and P22 and their heteroclitic peptides Py101, P22v, and Py22v for HLA-A*0201 molecules. DKK1 peptide P66 and its heteroclitic peptide P66v were used as controls in (A). In (A) T2 cells were incubated with 100 µg/mL peptides overnight, and in (B) T2 cells were incubated with 100 µg/mL peptides for different time points, and analyzed for surface HLA-A*0201 expression. Details are provided in the Methods section. Representative results of three independent experiments are shown.